DESIGN CHARACTERIZATION OPTIMIZATION OF LENALIDOMIDE-LOADED BOVINE SERUM ALBUMIN NANOPARTICLES FOR MYELOMA THERAPY
DOI:
https://doi.org/10.22159/ijap.2026v18i1.55623Keywords:
BSA, Nanoparticle, Myeloma, Optimization, LenalidomideAbstract
Objective: The present investigation focuses on the formulation and optimization of lenalidomide (LD)-loaded bovine serum albumin (BSA) nanoparticles (NPs) using the desolvation method. Box-Behnken design (BBD) was implemented to optimize the formulation.
Methods: The desolvation technique was employed to synthesize BSA-NPs encapsulating LD and characterized by particle size analysis, zeta potential, and transmission electron microscopy (TEM) analysis.
Results: The findings confirmed that the uniform spherical NPs were formed below 200 nm. Particle size found in the range of 110.9±13.02 nm to 182.8±10.33 nm, entrapment efficiency (EE) found between 60.1±9.01% and 94.80±9.14% and zeta potential-15.3±0.21mV to-29.7 ±0.12mV. A sudden burst release of approximately 55.68% was observed within 4 h from optimized LD BSA NPs (Opt-LD-BSA-NPs), followed by a slower release over 24 h. In vitro, cytotoxicity assays demonstrated selective toxicity against U266 cancer cells. The Opt-LD-BSA-NPs exhibited a significantly lower half-maximal inhibitory concentration (IC50) of 29.70%, indicating enhanced cytotoxic efficacy. Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses indicated successful drug entrapment and a transition of LD from a crystalline to an amorphous form. The area under curve (AUC) for Opt-LD-BSA-NPs was found to be 22.47 µg/ml/hr, which is 3 times more than the pure LD suspension (6.3025 µg/ml/h). It revealed enhanced bioavailability.
Conclusion: These findings underscore the potential of BSA-based nanocarriers to enhance the solubility, stability, and therapeutic efficacy of hydrophobic anticancer agents, such as LD.
References
1. Al Ostoot FH, Salah S, Khanum SA. An overview of cancer biology, pathophysiological development and it’s treatment modalities: current challenges of cancer anti-angiogenic therapy. Cancer Investig. 2024 Aug 8;42(7):559-604. doi: 10.1080/07357907.2024.2361295, PMID 38874308.
2. Sriharikrishnaa S, Suresh PS, Prasada S. An introduction to fundamentals of cancer biology. In: Mazumder N, Kistenev YV, Borisova E, Prasada KS, editors. Optical polarimetric modalities for biomedical research. Berlin: Springer International Publishing; 2023 Jul 23. p. 307-30. doi: 10.1007/978-3-031-31852-8_11.
3. Sobti RC, Gosipatala SB, Sharma M, Reddy P, Khalko RK, Kaur T. Types of cancers, epidemiology and molecular insights. In: Sobti RC, Ganguly NK, Kumar R, editors. Handbook of Oncobiology: from Basic to Clinical Sciences. Singapore: Springer Nature; 2023 Oct 10. p. 1-36. doi: 10.1007/978-981-99-2196-6_1-1.
4. Ahmad I, Jasim SA, Sharma MK, S RJ, Hjazi A, Mohammed JS. New paradigms to break barriers in early cancer detection for improved prognosis and treatment outcomes. J Gene Med. 2024 Aug;26(8):e3730. doi: 10.1002/jgm.3730, PMID 39152771.
5. Ahmed MB, Alghamdi AA, Islam SU, Ahsan H, Lee YS. The complex roles of DNA repair pathways inhibitors, hyperthermia and contact inhibition in cell cycle halts. Mini Rev Med Chem. 2023 Mar 1;23(5):514-29. doi: 10.2174/1389557522666220826141837, PMID 36029081.
6. Mazingi D, Lakhoo K. Cancer development and progression and the hallmarks of cancer. In: Lakhoo K, Abdelhafeez AH, Abib S, editors. Pediatric surgical oncology. Berlin: Springer International Publishing; 2023 Jun 14. p. 1-15. doi: 10.1007/978-3-030-71113-9_23-1.
7. Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1, PMID 36859359.
8. Wang Y, Iqbal H, Ur Rehman U, Zhai L, Yuan Z, Razzaq A. Albumin-based nanodevices for breast cancer diagnosis and therapy. J Drug Deliv Sci Technol. 2023 Jan 1;79:104072. doi: 10.1016/j.jddst.2022.104072.
9. Behera S, Mohanty P, Dash PP, Mohapatra P, Shubhadarshinee L, Behura R. Selective binding of bovine serum albumin (BSA): a comprehensive review. Biointerface Res Appl Chem. 2023;13(6):555. doi: 10.33263/BRIAC136.555.
10. Mardikasari SA, Katona G, Csoka I. Serum albumin in nasal drug delivery systems: exploring the role and application. Pharmaceutics. 2024 Oct 11;16(10):1322. doi: 10.3390/pharmaceutics16101322, PMID 39458651.
11. Lawal RA, Banjoko O, Ndulue C, Adebeshin ST, Sharif A, Ighodaro OE. Improved side effect profile of alternate-day dosing of lenalidomide. Cureus. 2024 Mar 1;16(3):e55317. doi: 10.7759/cureus.55317, PMID 38559519.
12. Banchi M, Cox MC, Bocci G. Metronomic chemotherapy in hematology: lessons from preclinical and clinical studies to build a solid rationale for future schedules. Cancer Lett. 2024 Jun 1;591:216900. doi: 10.1016/j.canlet.2024.216900, PMID 38636896.
13. Takahashi Y, Nagamine A, Kaneta A, Yashima H, Obayashi K, Araki T. Risk of exposure of patients family members to lenalidomide at home. Eur J Hosp Pharm. 2024 Nov 1;31(6):555-9. doi: 10.1136/ejhpharm-2022-003632, PMID 37339864.
14. Nadeem O, Ailawadhi S, Khouri J, Williams L, Catamero D, Maples K. Management of adverse events associated with pomalidomide-based combinations in patients with relapsed/refractory multiple myeloma. Cancers. 2024 Feb 29;16(5):1023. doi: 10.3390/cancers16051023, PMID 38473381.
15. Screen MA, Tomkinson G, McCabe JF, Askin S, Mahon CS, Wilson MR. Designing lenalidomide cocrystals with an extended release profile for improved pulmonary drug delivery. New J Chem. 2025;49(16):6535-43. doi: 10.1039/D5NJ00425J.
16. Gupta A, Moorkoth S, Moorkoth S, Dhas N. Central composite design aided optimization and validation of developed an eco-friendly HPLC method for the quantification of lenalidomide loaded mesoporous silica nanoparticles. J Appl Pharm Sci. 2024 Nov 25;15(1):89-101. doi: 10.7324/JAPS.2024.189998.
17. Aghaei Delche N, Kheiri R, Ghorbani Nejad B, Sheikhi M, Razavi MS, Rahimzadegan M. Recent progress in the intranasal PLGA-based drug delivery for neurodegenerative diseases treatment. Iran J Basic Med Sci. 2023;26(10):1107-19. doi: 10.22038/IJBMS.2023.70192.15264, PMID 37736505.
18. Kono Y, Sugaya T, Yasudome H, Ogiso H, Ogawara KI. Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking. Biochem Biophys Rep. 2024 Jul 1;38:101713. doi: 10.1016/j.bbrep.2024.101713, PMID 38681670.
19. Hsu WH, Ku CL, Lai YR, Wang SS, Chou SH, Lin TH. Developing targeted drug delivery carriers for breast cancer using glutathione-sensitive doxorubicin-coupled glycated bovine serum albumin nanoparticles. Int J Biol Macromol. 2023 Sep 30;249:126114. doi: 10.1016/j.ijbiomac.2023.126114, PMID 37541475.
20. Yang S, Diao Y, Hang L, Qu H, Fang L, Guo W. BSA@IR780-loaded mesoporous polydopamine nanoparticles with enhanced photostability for multimodal imaging and photothermal therapy of tumors. Nanoscale Adv. 2025;7(8):2182-94. doi: 10.1039/D5NA00008D, PMID 40007568.
21. Hasan HJ, Ghareeb MM. Optimizing desolvation conditions for glutathione-cross-linked bovine serum albumin nanoparticles: implication for intravenous drug delivery. Cureus. 2024 Sep 16;16(9):e69514. doi: 10.7759/cureus.69514, PMID 39416524.
22. Behram T, Pervez S, Nawaz MA, Ahmad S, Jan AU, Rehman HU. Development of pectinase-based nanocatalyst by immobilization of pectinase on magnetic iron oxide nanoparticles using glutaraldehyde as crosslinking agent. Molecules. 2023 Jan 3;28(1):404. doi: 10.3390/molecules28010404, PMID 36615596.
23. Maiti R, Panigrahi S, Yin T, Huo M. Bovine serum albumin nanoparticles: constructing procedures on anticancer activities. Int J Adv Res Biol Sci. 2018;5(4):226-39. doi: 10.22192/ijarbs.
24. Jena S, Aksan A. Effect of high DMSO concentration on albumin during freezing and vitrification. RSC Adv. 2017;7(69):43611-20. doi: 10.1039/C7RA07556A.
25. Jahanshahi M, Najafpour G, Rahimnejad M. Applying the Taguchi method for optimized fabrication of bovine serum albumin (BSA) nanoparticles as drug delivery vehicles. Afr J Biotechnol. 2008;7(4):362-7. doi: 10.5897/AJB07.843.
26. Karri VV, Dhandapani NV, Mannemala SS, Radhakrishna K, Mulukutla S, Sudunagunta D. Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma. Braz J Pharm Sci. 2017 Jun 22;53(2):e15185. doi: 10.1590/s2175-97902017000215185.
27. Panda N, Charan Panda K, Reddy AV, Reddy GV. Process optimization formulation and evaluation of hydrogel {guar gum-g-poly (acrylamide)} based doxofylline microbeads. Asian J Pharm Clin Res. 2014 Jul 1;7(3):60-5.
28. Mansour A, Fytory M, Ahmed OM, Rahman FE, El Sherbiny IM. In vitro and in vivo assessment of pH-responsive core-shell nanocarrier system for sequential delivery of methotrexate and 5-fluorouracil for the treatment of breast cancer. Int J Pharm. 2023 Dec 15;648:123608. doi: 10.1016/j.ijpharm.2023.123608, PMID 37972670.
29. Niranjan P, Reddy AV, Reddy GV, Panda KC. Formulation design and in vitro evaluation of zolmitriptan immediate release tablets using primojel and Ac-di-Sol. J Pharm Sci Res. 2015;7(8):545-53.
30. Sharma V, Sundaramurthy A. Surface modification of bare copper grids with charged polymers: a simple alternative for carbon-coated copper grids in transmission electron microscopy. Mater Lett. 2022 Feb 1;308:131204. doi: 10.1016/j.matlet.2021.131204.
31. Silva F, Sitia L, Allevi R, Bonizzi A, Sevieri M, Morasso C. Combined method to remove endotoxins from protein nanocages for drug delivery applications: the case of human ferritin. Pharmaceutics. 2021 Feb 6;13(2):229. doi: 10.3390/pharmaceutics13020229, PMID 33562060.
32. Terzi H, Altun A, Sencan M. In vitro comparison of the cytotoxic effects of statins on U266 myeloma cell line. Indian J Med Res. 2019 Dec 1;150(6):630-4. doi: 10.4103/ijmr.IJMR_672_18, PMID 32048627.
33. Panda N, Reddy AV, Reddy GV, Panda KC. Effect of different grades of HPMC and eudragit on drug release profile of doxofylline sustained release matrix tablets and IVIVC studies. Int Res J Pharm. 2015;6(8):493-504. doi: 10.7897/2230-8407.068100.
34. Tanjung YP, Dewi MK, Gatera VA, Barliana MI, Joni IM, Chaerunisaa AY. Factors affecting the synthesis of bovine serum albumin nanoparticles using the desolvation method. Nanotechnol Sci Appl. 2024 Dec 31;17:21-40. doi: 10.2147/NSA.S441324, PMID 38314401.
35. Wallerstein J, Akke M. Minute additions of DMSO affect protein dynamics measurements by NMR relaxation experiments through significant changes in solvent viscosity. ChemPhysChem. 2019 Jan 21;20(2):326-32. doi: 10.1002/cphc.201800626, PMID 30102005.
36. Magalhaes IS, Maurilio KB, De Souza DA, Tribst AA, Leite Junior BR. Application of roasting ultrasound and high-shear dispersion in pea protein extraction: yield parameters, macrostructural characteristics and technical functional properties. Food Bioprocess Technol. 2025 Apr 21;18(7):6550-63. doi: 10.1007/s11947-025-03852-3.
37. Spada A, Emami J, Tuszynski JA, Lavasanifar A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol Pharm. 2021 Mar 31;18(5):1862-94. doi: 10.1021/acs.molpharmaceut.1c00046, PMID 33787270.
38. Shalmani AA, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl EM. Tunable polymeric micelles for taxane and corticosteroid co-delivery. Drug Deliv Transl Res. 2024 Oct;14(10):2642-54. doi: 10.1007/s13346-023-01465-x, PMID 37962836.
39. Zaibudeen AW, Philip J. Adsorption of bovine serum albumin at oil-water interface in the presence of polyelectrolytes and nature of interaction forces. Colloids Surf A Physicochem Eng Aspects. 2019 Apr 5;566:38-47. doi: 10.1016/j.colsurfa.2019.01.014.
40. Wilson BK, Prudhomme RK. Nanoparticle size distribution quantification from transmission electron microscopy (TEM) of ruthenium tetroxide-stained polymeric nanoparticles. J Colloid Interface Sci. 2021 Dec 15;604:208-20. doi: 10.1016/j.jcis.2021.04.081, PMID 34265681.
41. Virani HA, Upadhyay MS, Pargi PM, Ashish P, Anovadiya. Evaluation of hypolipidemic activity of Opuntia elatior fruit juice in high-fat diet-induced hyperlipidemia in Wistar albino rats. Asian Journal of Pharmaceutical and Clinical Research. 2025;18(7):240-4. doi: 10.22159/ajpcr.2025v18i7.54619.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Dr. Niranjan Panda, Sameena Begum, Dr. Ch. Praveena
This work is licensed under a Creative Commons Attribution 4.0 International License.